Search Results | Blood | American Society of Hematology

1-20 of 116

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma

Seth Welsh, Daniel Riggs, Erin Meermeier, Chang-Xin Shi, Victoria Garbitt, Meaghen E Sharik, Megan Du, Kennedi Todd, Zachary Hammond, Sochilt Brown, Caleb K Stein, Paola Neri, Nizar J. Bahlis, Benjamin G Barwick, Larry H. Boise, W. Michael Kuehl, Marta Chesi, P. Leif Bergsagel

Blood (2021) 138 (Supplement 1): 1593.

DOI: https://doi.org/10.1182/blood-2021-147551

Published: 2021

Journal Articles

Integrated Epigenetic and Transcriptional Single Cell Analysis of t(11;14) Myeloma and Its BCL2 Dependency

Noemie Leblay, Sungwoo Ahn, Ranjan Maity, Holly Lee, Elie Barakat, Nizar J. Bahlis, Paola Neri

Blood (2021) 138 (Supplement 1): 725.

DOI: https://doi.org/10.1182/blood-2021-152993

Published: 2021

Journal Articles

Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers

Mirco Friedrich, Paola Neri, Noemie Leblay, Niklas Kehl, Julius Michel, Holly Lee, Elie Barakat, Sungwoo Ahn, Hartmut Goldschmidt, Michael Platten, Niels Weinhold, Marc-Steffen Raab, Nizar J. Bahlis

Blood (2021) 138 (Supplement 1): 731.

DOI: https://doi.org/10.1182/blood-2021-152149

Published: 2021

Journal Articles

A BCL2L1 Armoured BCMA Targeting CAR T Cell to Overcome Exhaustion and Enhance Persistence in Multiple Myeloma

Ranjan Maity, Sacha Benaoudia, Franz Zemp, Holly Lee, Elie Barakat, Noemie Leblay, Sungwoo Ahn, Douglas Mahoney, Paola Neri, Nizar J. Bahlis

Blood (2021) 138 (Supplement 1): 327.

DOI: https://doi.org/10.1182/blood-2021-153871

Published: 2021

Journal Articles

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Sarah Gooding, Naser Ansari-Pour, Fadi Towfic, María Ortiz Estévez, Philip P. Chamberlain, Kao-Tai Tsai, Erin Flynt, Marissa Hirst, Dan Rozelle, Paula Dhiman, Paola Neri, Karthik Ramasamy, Nizar Bahlis, Paresh Vyas, Anjan Thakurta

Blood (2021) 137 (2): 232–237.

DOI: https://doi.org/10.1182/blood.2020007081

Published: 2021

Includes: Supplemental data

Journal Articles

Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

Noemie Leblay, PhD, Ranjan Maity, PhD, Elie Barakat, Sylvia McCulloch, MD MSc, Peter Duggan, MD FRCPC, Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Paola Neri, MD

Blood (2020) 136 (Supplement 1): 11–12.

DOI: https://doi.org/10.1182/blood-2020-137650

Published: 2020

Journal Articles

Immune Deregulation in Active Multiple Myeloma

Paola Neri, MD

Blood (2020) 136 (Supplement 1): SCI5.

DOI: https://doi.org/10.1182/blood-2020-133077

Published: 2020

Journal Articles

Clonal hematopoiesis in myeloma: root of all maladies!

Paola Neri

Blood (2020) 135 (26): 2330–2331.

DOI: https://doi.org/10.1182/blood.2020005967

Published: 2020

Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 4742.

DOI: https://doi.org/10.1182/blood-2019-124191

Published: 2019

Journal Articles

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Jean-Baptiste Alberge, Sarthak Sinha, BSc, Ranjan Maity, PhD, Arzina Jaffer, Justin Donovan, Madison Kong, Stephane Minvielle, PhD, Paola Neri, MD PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 686.

DOI: https://doi.org/10.1182/blood-2019-131981

Published: 2019

Journal Articles

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Paola Neri, MD PhD, Ranjan Maity, PhD, Jean-Baptiste Alberge, Sarthak Sinha, BSc, Justin Donovan, Madison Kong, Fajer Hasan, Arzina Jaffer, Lawrence H. Boise, PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 572.

DOI: https://doi.org/10.1182/blood-2019-127593

Published: 2019

Journal Articles

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Sarah Gooding, FRCPath,MRCP,MBBChir, Naser Ansari-Pour, PhD, Fadi Towfic, PhD, Maria Ortiz, Dan Rozelle, PhD, Victoria Zadorozhny, Michael Amatangelo, Erin Flynt, Kao-Tai Tsai, Paola Neri, MD PhD, Nizar Bahlis, MD, Paresh Vyas, MD PhD, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 1793.

DOI: https://doi.org/10.1182/blood-2019-126828

Published: 2019

Journal Articles

The Pandora’s box of thalidomide analogs and their substrates

Paola Neri

Blood (2019) 134 (2): 105–106.

DOI: https://doi.org/10.1182/blood.2019001420

Published: 2019

Journal Articles

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Nizar J. Bahlis, Heather Sutherland, Darrell White, Michael Sebag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, Cristina Gasparetto, Aldo Del Col, Paola Neri, Donna Reece, Michael Kauffman, Sharon Shacham, T. J. Unger, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, Christine Chen

Blood (2018) 132 (24): 2546–2554.

DOI: https://doi.org/10.1182/blood-2018-06-858852

Published: 2018

Includes: Supplemental data

Journal Articles

Identification of Specificity Groups in Myeloma Patients T Cell Receptor (TCR) Repertoire through Single Cell TCR Sequencing

Paola Neri, MD, Ranjan Maity, PhD, Sylvia McCulloch, MD, Peter Duggan, MD, Victor Jimenez-Zepeda, MD, Jason Tay, MD, Nizar Bahlis, MD

Blood (2018) 132 (Supplement 1): 4459.

DOI: https://doi.org/10.1182/blood-2018-99-117482

Published: 2018

Journal Articles

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Shannon M Matulis, PhD, Vikas A. Gupta, MD PhD, Izabelle Brown, Jonathan J Keats, PhD, Paul Secrist, PhD, Justin Cidado, PhD, Adriana E. Tron, PhD, Paola Neri, MD, Nizar Bahlis, MD, Jonathan L Kaufman, MD, Leonard Heffner, MD, Sagar Lonial, MD, Ajay K Nooka, MDMPH, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 952.

DOI: https://doi.org/10.1182/blood-2018-99-113504

Published: 2018

Journal Articles

Enhancer Deregulation in Myeloma

Paola Neri, MD

Blood (2018) 132 (Supplement 1): SCI-38.

DOI: https://doi.org/10.1182/blood-2018-99-109523

Published: 2018

Journal Articles

Monoclonal Gammopathy of Clinical Significance - a Single Center Experience

Holly Lee, MD, Lesley Street, MD, Jason Tay, MD, Jennifer Grossman, MD, John F Thaell, MD, Dawn Goodyear, MD, Sylvia McCulloch, MD, Peter Duggan, MD, Paola Neri, MD, Victor Jimenez-Zepeda, MD

Blood (2018) 132 (Supplement 1): 4495.

DOI: https://doi.org/10.1182/blood-2018-99-117819

Published: 2018

Journal Articles

Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns

Holly Lee, MD, Lesley Street, MD, Jason Tay, MD, Jennifer Grossman, MD, John F Thaell, MD, Dawn Goodyear, MD, Sylvia McCulloch, MD, Peter Duggan, MD, Paola Neri, MD, Victor Jimenez-Zepeda, MD

Blood (2018) 132 (Supplement 1): 4496.

DOI: https://doi.org/10.1182/blood-2018-99-117930

Published: 2018

Journal Articles

Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy

Benjamin G Barwick, PhD, Paola Neri, MD, Nizar Bahlis, MD, Ajay K Nooka, MDMPH, Jonathan L Kaufman, MD, Vikas A. Gupta, MD PhD, Daniel Auclair, PhD, Jonathan J Keats, PhD, Sagar Lonial, MD, Paula M Vertino, PhD, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 405.

DOI: https://doi.org/10.1182/blood-2018-99-113585

Published: 2018

2 3 4 5

NARROW

Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma

Integrated Epigenetic and Transcriptional Single Cell Analysis of t(11;14) Myeloma and Its BCL2 Dependency

Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers

A BCL2L1 Armoured BCMA Targeting CAR T Cell to Overcome Exhaustion and Enhance Persistence in Multiple Myeloma

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

Immune Deregulation in Active Multiple Myeloma

Clonal hematopoiesis in myeloma: root of all maladies!

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

The Pandora’s box of thalidomide analogs and their substrates

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Identification of Specificity Groups in Myeloma Patients T Cell Receptor (TCR) Repertoire through Single Cell TCR Sequencing

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Enhancer Deregulation in Myeloma

Monoclonal Gammopathy of Clinical Significance - a Single Center Experience

Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns

Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only